Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'
Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies. The post Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake' appeared first on Investor's Business Daily.
Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
The post Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake' appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
